Induction of interferon-γ from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-α and tumour necrosis factor-α

被引:66
作者
Marshall, JD [1 ]
Heeke, DS [1 ]
Abbate, C [1 ]
Yee, P [1 ]
Van Nest, G [1 ]
机构
[1] Dynavax Technol Corp, Berkeley, CA 94710 USA
关键词
CpG DNA; interferon-alpha; interferon-gamma; natural killer cells; plasmacytoid dendritic cells;
D O I
10.1111/j.1365-2567.2005.02261.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunostimulatory sequences (ISS) that contain CpG motifs have been demonstrated to exert antipathogen and antitumour immunity in animal models through several mechanisms, including the activation of natural killer (NK) cells to secrete interferon-gamma (IFN-gamma) and to exert lytic activity. Since NK cells lack the ISS receptor TLR9, the exact pathway by which NK cells are activated by ISS is unclear. We determined that ISS-induced IFN-gamma from NK cells is primarily dependent upon IFN-alpha release from plasmacytoid dendritic cells (PDCs), which directly activates the NK cell. However, further analysis indicated that other PDC-released soluble factor(s) may contribute to IFN-gamma induction. Indeed, tumour necrosis factor-alpha (TNF-alpha) was identified as a significant contributor to ISS-mediated activation of NK cells and was observed to act in an additive fashion with IFN-alpha in the induction of IFN-gamma from NK cells and to up-regulate CD69 expression on NK cells. This activity of TNF-alpha, however, was dependent upon the presence of PDC-derived factors such as type I interferon. These results illustrate an important function for type I interferon in innate immunity, which is not only to activate effectors like NK cells directly, but also to prime them for enhanced activation by other factors such as TNF-alpha.
引用
收藏
页码:38 / 46
页数:9
相关论文
共 48 条
  • [41] Functional analysis of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte receptors
    Sancho, D
    Santis, AG
    Alonso-Lebrero, JL
    Viedma, F
    Tejedor, R
    Sánchez-Madrid, F
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (07) : 3868 - 3875
  • [42] Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice
    Shah, JA
    Darrah, PA
    Ambrozak, DR
    Turon, TN
    Mendez, S
    Kirman, J
    Wu, CY
    Glaichenhaus, N
    Seder, RA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (02) : 281 - 291
  • [43] CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells
    Sivori, S
    Falco, M
    Della Chiesa, M
    Carlomagno, S
    Vitale, M
    Moretta, L
    Moretta, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (27) : 10116 - 10121
  • [44] IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells
    Strengell, M
    Matikainen, S
    Sirén, J
    Lehtonen, A
    Foster, D
    Julkunen, I
    Sareneva, T
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (11) : 5464 - 5469
  • [45] The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses
    Trinchieri, G
    Pflanz, S
    Kastelein, RA
    [J]. IMMUNITY, 2003, 19 (05) : 641 - 644
  • [46] Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12-and IFN-γ-dependent mechanisms
    Walker, PS
    Scharton-Kersten, T
    Krieg, AM
    Love-Homan, L
    Rowton, ED
    Udey, MC
    Vogel, JC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6970 - 6975
  • [47] Weigel BJ, 2003, CLIN CANCER RES, V9, P3105
  • [48] Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
    Zwaveling, S
    Mota, SCF
    Nouta, J
    Johnson, M
    Lipford, GB
    Offringa, R
    van der Burg, SH
    Melief, CJM
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (01) : 350 - 358